Optimizing Outcomes and an Equitable Healthcare Experience for All Patients With Gynecologic Cancers

Join us for a live CME/CNE/CPE-certified Interdisciplinary Team Workshop Series to hear from experts on improving health equity for patients with endometrial, ovarian, and cervical cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome, Introduction, Polling, and Presurvey Questions

Achieving Health Equity in Endometrial Cancers

  • Endometrial cancer overview
  • Defining racial disparities in the healthcare experience
    • Improving communication/trust with patients
    • Discussion of molecular testing informing treatment options
  • Management of adverse events with novel treatments
  • Benefits of guideline concordant care
    • Novel therapies in development
    • Case-based discussion of current data

Achieving Health Equity in Ovarian Cancers

  • Ovarian cancer overview
  • Defining racial disparities in the healthcare experience
  • Current management of ovarian cancer
    • Testing for BRCA1/2 and HRD status
  • Benefits of guideline concordant care
    • Novel therapies in development
    • Case-based discussion of current data

Achieving Health Equity in Cervical Cancers

  • Cervix cancer overview
  • Defining racial disparities in the healthcare experience
    • HPV infection and tumorigenesis
    • HPV vaccination and preventative measures
  • Current management of advanced/metastatic cervix cancer
    • Role of surgery and chemoradiation in cervix cancer
  • New and emerging therapies for cervical cancer
    • Case-based discussion of current data

Audience Question and Answer Session


Date / Time
Event Details


Program Chair
Eloise Chapman-Davis, MD, FACOG

Gynecologic Oncologist
Associate Professor of OB/GYN
Department of OB/GYN
Division of Gynecologic Oncology
Weill Cornell Medicine-NewYork Presbyterian Hospital
New York, New York

Program Chair
Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Hye Sook Chon, MD

Associate Professor
Associate Member
Clinical Trials Medical Director
Department of Gynecologic Oncology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Linda R. Duska, MD, MPH

Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Whitney S. Graybill, MD, MS, FACOG

Division Director, Gynecologic Oncology
Director, MUSC Robotic Surgery
Medical University of South Carolina
Charleston, South Carolina

Lauren S. Prescott, MD

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals, as well as patients/caregivers, about recent developments in the care of gynecologic malignancies and to raise awareness of disparities in care to optimize and individualize the treatment experience for every patient.

Target Audience
This educational program is intended for oncologists, oncology nurses, oncology pharmacists, and other healthcare professionals who care for patients with gynecologic malignancies, as well as patients with gynecologic cancers and their caregivers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with cervical, endometrial, and ovarian cancers, considering the available clinical data, expert recommendations, and patient preferences
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Individualize immune checkpoint inhibitor–based therapy in endometrial and cervical cancer based on unique tumor and patient characteristics
  • Use available resources to effectively communicate with patients the risk factors and importance of screening, the therapeutic and prognostic implications for evidence-based molecular profiling, and the benefits of clinical trial enrollment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-031-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.